Abstract

TREATMENTS DISCOVERY SO FAR ON SARS-COVID-19: A BRIEF REPORT

Nobendu Mukerjee, Aloke Kumar Ghosh and Dr. Malay Dolai*

Abstract

After the attack of Influenza virus (also known as Flu virus) in the year 1918 which after turned to be a pandemic, now the world is again facing a similar situation since March 2020. However, with the advancement in field of medicinal science has made it possible to identify the novel infectious agent from the corona-viridae family. SARS-CoV-2 belongs to the broad family of viruses known as coronaviruses. It is a positive-sense single-stranded RNA virus, with a single linear RNA segment. Other coronaviruses are capable of causing illnesses ranging from the common cold to more severe diseases such as Middle East respiratory syndrome (MERS, fatality rate ~34%). Rapid sequencing by various groups helped in identifying the structure and function of the virus, it’s immunogenicity in diverse populations, and potential preventive measures. As of December 2020 there were over 150+ vaccine candidates for COVID-19 being developed. Out of these, at least 52 candidate vaccines are initiated for trials in human model. There are several others currently in phase 2/3 which would enter at 3rd phase in the few months.

Keywords: Immune response, Placebo, Immunoresponse, drug repurposing and remodeling, SARS-CoV-2.